Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 22.64%28.12B | 29.91%11.44B | 11.33%6.48B | 39.76%6.21B | 3.43%4B | -7.31%22.93B | 3.81%8.81B | 2.32%5.82B | -17.00%4.44B | -25.95%3.86B |
Cost of revenue | 20.40%22.74B | 35.05%9.38B | 11.00%5.11B | 21.00%4.74B | 2.62%3.52B | -11.25%18.89B | -2.33%6.94B | -0.99%4.6B | -19.05%3.92B | -26.90%3.43B |
Gross profit | 33.15%5.38B | 10.71%2.06B | 12.58%1.37B | 179.53%1.47B | 9.76%477.24M | 16.96%4.04B | 35.56%1.86B | 17.16%1.22B | 2.24%525.57M | -17.54%434.79M |
Operating expense | -1.05%4.46B | -7.53%1.03B | -3.83%1.03B | -3.66%1.14B | 10.70%1.25B | 5.45%4.5B | 9.13%1.12B | 3.34%1.07B | 6.22%1.18B | 3.24%1.13B |
Operating profit | 296.94%919.01M | 38.11%1.03B | 138.41%334.24M | 150.95%333.07M | -11.29%-775.84M | 43.02%-466.65M | 113.09%743.99M | 4,759.19%140.2M | -9.67%-653.67M | -22.50%-697.16M |
Net non-operating interest income (expenses) | -112.02%-125.42M | -42.27%-32.2M | -126.64%-32.26M | -203.79%-31.98M | -146.36%-28.99M | -107.93%-59.16M | -125.07%-22.63M | -102.48%-14.23M | -248.69%-10.53M | -40.96%-11.77M |
Non-operating interest income | -1.65%119K | 0.00%25K | 8.70%25K | -28.57%25K | 15.79%44K | 14.15%121K | -26.47%25K | 76.92%23K | 20.69%35K | 26.67%38K |
Non-operating interest expense | 111.79%125.54M | 42.23%32.22M | 126.45%32.28M | 203.02%32.01M | 145.94%29.03M | 107.58%59.28M | 124.56%22.66M | 102.43%14.26M | 246.52%10.56M | 40.90%11.81M |
Net investment income | -239.83%-24.55M | -495.41%-18.42M | -24.93%20.53M | 20.48%-10.49M | -1,185.85%-16.18M | -2.71%17.56M | -51.56%4.66M | 1,270.76%27.35M | -1,177.61%-13.19M | -113.18%-1.26M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -292.28%-39.28M | -570.06%-87.1M | -17.48%1.57M | 14.57M | 31.68M | 20.43M | 18.53M | 1.9M | 0 | 0 |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 0 | -171.57%-1.16M | -101.03%-221K | 97.30%-205K | -83.34%1.58M | 173.94%24.98M | 104.45%1.62M | 16,402.31%21.45M | -2,889.37%-7.59M | 256.16%9.51M |
Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---24.98M | ---3.45M | ---- | ---- | ---7.52M |
Less:Write off | ---- | ---- | 169.51%221K | 166.23%205K | 20.40%-1.58M | ---- | ---- | 163.08%82K | -69.69%77K | 25.44%-1.99M |
Other non-operating income (expenses) | 41.67%70.83M | 317.49%29.97M | -51.17%16.49M | -35.92%11.19M | 5.13%13.19M | 45.14%50M | -92.86%-13.78M | 120.59%33.78M | 11.05%17.46M | 18.77%12.55M |
Income before tax | 293.92%800.58M | 25.43%918.62M | 61.73%340.36M | 147.36%316.16M | -12.56%-774.55M | 50.19%-412.84M | 139.94%732.38M | 6,763.70%210.44M | -14.62%-667.53M | -24.06%-688.13M |
Income tax | -132.75%-85.95M | -181.95%-87M | -66.74%66.89M | 142.85%10.78M | -289.47%-76.62M | 154.05%262.46M | -4.65%106.16M | 137.55%201.12M | 55.60%-25.15M | 45.43%-19.67M |
Net income | 231.28%886.53M | 60.58%1.01B | 2,834.18%273.47M | 147.54%305.38M | -4.41%-697.93M | 27.55%-675.29M | 222.98%626.22M | 111.42%9.32M | -22.18%-642.38M | -28.89%-668.46M |
Net income continuous operations | 231.28%886.53M | 60.58%1.01B | 2,833.88%273.47M | 147.54%305.38M | -4.41%-697.93M | 27.55%-675.29M | 222.98%626.22M | 111.42%9.32M | -22.18%-642.38M | -28.89%-668.46M |
Noncontrolling interests | -6.99%127.02M | -6.24%127.01M | -2.14%37.73M | 120.15%7.19M | -2,475.29%-44.91M | 49.30%136.57M | 9.61%135.46M | -39.67%38.56M | -11.66%-35.7M | 97.28%-1.74M |
Net income attributable to the company | 193.55%759.51M | 79.03%878.61M | 906.23%235.73M | 149.15%298.19M | 2.05%-653.02M | 20.68%-811.86M | 598.01%490.77M | 79.91%-29.24M | -22.87%-606.68M | -46.67%-666.71M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 193.55%759.51M | 79.03%878.61M | 906.23%235.73M | 149.15%298.19M | 2.05%-653.02M | 20.68%-811.86M | 598.01%490.77M | 79.91%-29.24M | -22.87%-606.68M | -46.67%-666.71M |
Gross dividend payment | ||||||||||
Basic earnings per share | 193.47%583.3 | 78.84%674.78 | 912.70%181.15 | 149.16%229.2 | 2.14%-501.83 | 20.81%-624.04 | 593.46%377.31 | 80.02%-22.29 | -22.68%-466.28 | -46.18%-512.78 |
Diluted earnings per share | 193.47%583.3 | 78.94%674.4891 | 905.46%180.9629 | 149.09%228.9056 | 2.14%-501.83 | 20.81%-624.04 | 597.48%376.9324 | 79.92%-22.467 | -22.68%-466.28 | -46.18%-512.78 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |